Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
Heart failure is a severe cardiovascular condition when the heart fails to adequately pump blood or oxygen to support the body’s organs. Sacubitril/valsartan, an emerging angiotensin receptor-neprilysin inhibitor (ARNI) known for its superior efficacy to conventional treatments, has revolutionized t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-04-01
|
| Series: | MGM Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/mgmj.mgmj_6_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586524015722496 |
|---|---|
| author | Neeraj Hiremath Jayasheela S. Hiremath Sanatkumar B. Nyamagoud Agadi Hiremath Viswanatha Swamy |
| author_facet | Neeraj Hiremath Jayasheela S. Hiremath Sanatkumar B. Nyamagoud Agadi Hiremath Viswanatha Swamy |
| author_sort | Neeraj Hiremath |
| collection | DOAJ |
| description | Heart failure is a severe cardiovascular condition when the heart fails to adequately pump blood or oxygen to support the body’s organs. Sacubitril/valsartan, an emerging angiotensin receptor-neprilysin inhibitor (ARNI) known for its superior efficacy to conventional treatments, has revolutionized the management of heart failure. The United States Food and Drug Administration has approved the drug’s use in treating patients with chronic heart failure with reduced ejection fraction (HFrEF). Clinical trials have demonstrated its effectiveness in reducing hospitalizations and mortality rates associated with heart failure across various patient populations, including those with low ejection fraction. Numerous significant clinical trials have investigated the drug’s safety and efficacy in treating individuals with heart failure and a failing systemic right ventricle. This review delves into the current landscape of cardiovascular medicine, the role of pharmacology, and the safety profile of this medication. |
| format | Article |
| id | doaj-art-9cc3859bca424acd8e032d6812097765 |
| institution | Kabale University |
| issn | 2347-7946 2347-7962 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | MGM Journal of Medical Sciences |
| spelling | doaj-art-9cc3859bca424acd8e032d68120977652025-01-25T10:19:23ZengWolters Kluwer Medknow PublicationsMGM Journal of Medical Sciences2347-79462347-79622024-04-0111234034410.4103/mgmj.mgmj_6_24Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination TherapyNeeraj HiremathJayasheela S. HiremathSanatkumar B. NyamagoudAgadi Hiremath Viswanatha SwamyHeart failure is a severe cardiovascular condition when the heart fails to adequately pump blood or oxygen to support the body’s organs. Sacubitril/valsartan, an emerging angiotensin receptor-neprilysin inhibitor (ARNI) known for its superior efficacy to conventional treatments, has revolutionized the management of heart failure. The United States Food and Drug Administration has approved the drug’s use in treating patients with chronic heart failure with reduced ejection fraction (HFrEF). Clinical trials have demonstrated its effectiveness in reducing hospitalizations and mortality rates associated with heart failure across various patient populations, including those with low ejection fraction. Numerous significant clinical trials have investigated the drug’s safety and efficacy in treating individuals with heart failure and a failing systemic right ventricle. This review delves into the current landscape of cardiovascular medicine, the role of pharmacology, and the safety profile of this medication.https://doi.org/10.4103/mgmj.mgmj_6_24angiotensin receptor-neprilysin inhibitorcardiorenal syndromeejection fractionheart failuresacubitril/valsartan |
| spellingShingle | Neeraj Hiremath Jayasheela S. Hiremath Sanatkumar B. Nyamagoud Agadi Hiremath Viswanatha Swamy Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy MGM Journal of Medical Sciences angiotensin receptor-neprilysin inhibitor cardiorenal syndrome ejection fraction heart failure sacubitril/valsartan |
| title | Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy |
| title_full | Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy |
| title_fullStr | Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy |
| title_full_unstemmed | Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy |
| title_short | Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy |
| title_sort | progress in managing heart failure an in depth review of sacubitril valsartan combination therapy |
| topic | angiotensin receptor-neprilysin inhibitor cardiorenal syndrome ejection fraction heart failure sacubitril/valsartan |
| url | https://doi.org/10.4103/mgmj.mgmj_6_24 |
| work_keys_str_mv | AT neerajhiremath progressinmanagingheartfailureanindepthreviewofsacubitrilvalsartancombinationtherapy AT jayasheelashiremath progressinmanagingheartfailureanindepthreviewofsacubitrilvalsartancombinationtherapy AT sanatkumarbnyamagoud progressinmanagingheartfailureanindepthreviewofsacubitrilvalsartancombinationtherapy AT agadihiremathviswanathaswamy progressinmanagingheartfailureanindepthreviewofsacubitrilvalsartancombinationtherapy |